

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10577094	
	Filing Date		2006-04-26	
	First Named Inventor	Dietmar KRAUTWURST		
	Art Unit			
	Examiner Name			
Attorney Docket Number		102790-211/30246US		

U.S.PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6492143	B1	2002-10-12	Reed et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS								<a href="#">Remove</a>
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	02/006311	WO	A2	2002-01-24	Merck Patent GmbH		<input type="checkbox"/>
	2	2147402	AU			.		<input type="checkbox"/>
	3	1235859	EP	A				<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10577094	10577094 - GAU: 1646
Filing Date	2006-04-26	
First Named Inventor	Dietmar KRAUTWURST	
Art Unit		
Examiner Name		
Attorney Docket Number	102790-211/30246US	

4	02/059274	WO	A2	2002-08-01	Vanderbilt University		<input type="checkbox"/>
5	02/38605	WO	A1	2002-05-16	Shanghai Biowindow Gene Development Inc.		<input type="checkbox"/>
6	01/036484	WO	A1	2001-05-25	Merck Patent GmbH		<input type="checkbox"/>
7	1376691	CN		2002-10-30	Biowindow Gene Development Inc.		<input type="checkbox"/>
8	1376713	CN		2002-10-30	Biowindow Gene Development Inc.		<input type="checkbox"/>
9	1380323	CN		2002-11-20	Shanghai Biowindow Gene Development Inc.		<input type="checkbox"/>
10	1386760	CN		2002-12-25	Biowindow Gene Development Inc.		<input type="checkbox"/>
11	03/004611	WO	A2	2003-01-16	Senomyx, Inc.	Cited in the application; paragraph '0003; figure 9; examples 1, 3; page 2, line 10 – line 20	<input type="checkbox"/>
12	01/51609	WO	A1	2001-07-07	The Johns Hopkins University		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
--------------------	---------	---	----

/Sandra Wegert/

09/28/2009

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10577094	10577094 - GAU: 1646
Filing Date	2006-04-26	
First Named Inventor	Dietmar KRAUTWURST	
Art Unit		
Examiner Name		
Attorney Docket Number	102790-211/30246US	

1	Copy of International Search Report dated January 31, 2005 for application PCT/EP2004/012086	<input type="checkbox"/>
2	ILLING NICOLA ET AL.: "Conditionally immortalized clonal cell lines from the mouse olfactory placode differentiate into olfactory receptor neurons"; MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 20, no. 2, June 2002 (2002-06), pages 225-243, XP002315703; ISSN: 1044-7431; abstract	<input type="checkbox"/>
3	SHIROKOVA E. ET AL.: "Identification of specific ligands for orphan olfactory receptors: G-protein dependent agonism and antagonism of odorants"; JOURNAL OF BIOLOGICAL CHEMISTRY, "Onlinel, 14 December 2004 (2004-12-14), XP002315704; Retrieved from the Internet: URL:http://www.jbc.org/cgi/reprint/M411508200v1> retrieved on 2005-01-26; Published online ahead of print December 14, 2004; J. Biol. Chem., 10.1074/jbc.M411508200, page 3, left-hand column, laste line -- right-hand column, line 2	<input type="checkbox"/>
4	KAJIYA K ET AL.: "Molecular bases of odor discrimination: Reconstitution of olfactory receptors that recognize overlapping sets of odorants." THE JOURNAL OF NEUROSCIENCE: THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE. 15 AUG 2001, vol. 21, no. 16, 15 August 2001 (2001-08-15), pages 6018-6025, XP002315705; ISSN: 1529-2401; cited in the application; the whole document	<input type="checkbox"/>
5	WILSON S ET AL.: "ORPHAN G-PROTEIN-COUPLED RECEPTORS: THE NEXT GENERATION OF DRUG TARGETS?" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 125, no. 7, December 1998 (1998-12), pages 1387-1392, XP001010584; ISSN: 0007-1188; cited in the application; the whole document	<input type="checkbox"/>
6	REED R R: "Signaling pathways in odorant detection." NEURON, FEB 1992, vol. 8, no. 2, February 1992 (1992-02), page 205-209, XP002315707; ISSN: 0896-6273; figure 1	<input type="checkbox"/>
7	BRUZZONE R ET AL.: "CONNECTIONS WITH CONNEXINS: THE MOLECULAR BASIS OF DIRECT INTERCELLULAR SIGNALING"; EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 238, 1996, pages 1-27, XP002913288; ISSN: 0014-2956; the whole document	<input type="checkbox"/>
8	English language abstract of CN 1386760	<input type="checkbox"/>
9	English language abstract of CN 1380323	<input type="checkbox"/>
10	English language abstract of CN 1376713	<input type="checkbox"/>
11	English language abstract of CN 1376691	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10577094	10577094 - GAU: 1646
Filing Date	2006-04-26	
First Named Inventor	Dietmar KRAUTWURST	
Art Unit		
Examiner Name		
Attorney Docket Number	102790-211/30246US	

12 For AU2147402, an English language abstract for corresponding patent application WO 02/38605



If you wish to add additional non-patent literature document citation information please click the Add button **Add**

**EXAMINER SIGNATURE**

Examiner Signature	/Sandra Wegert/	Date Considered	09/28/2009
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10577094	10577094 - GAU: 1646
Filing Date	2006-04-26	
First Named Inventor	Dietmar KRAUTWURST	
Art Unit		
Examiner Name		
Attorney Docket Number	102790-211/30246US	

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☒ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.16. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-05-19
Name/Print	Andrew N. Parfomak	Registration Number	32431

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.